Strides Pharma Science 35th AGM on Aug 14, 2026: Dividend, Board Changes & Key Dates
Strides Pharma Science Limited has convened its 35th AGM on August 14, 2026, proposing a final dividend of ₹5 per equity share for FY 2025-26. Key board changes include the appointment of Mr. Venkata Seetharama Raju Pakalapati as Executive Director and the transition of Mr. Aditya Arun Kumar to Non-Executive Director. The company reported strong FY26 consolidated revenue of ₹48,587 Mn (+6.40% YoY), EBITDA of ₹9,253 Mn (+15.30%), and Operational PAT of ₹5,181 Mn (+50.30%).

*this image is generated using AI for illustrative purposes only.
Strides Pharma Science Limited has convened its 35th Annual General Meeting (AGM) on Friday, August 14, 2026, at 12:15 hrs IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM), in compliance with circulars issued by the Ministry of Corporate Affairs (MCA) and the Securities and Exchange Board of India (SEBI). The company has fixed Friday, July 31, 2026 as the record date to determine shareholder eligibility for a final dividend of ₹5 per equity share — representing 50% of the face value of ₹10 per share — for the financial year ended March 31, 2026. The dividend, recommended by the Board of Directors on May 18, 2026, is subject to shareholder approval at the AGM. If approved, the payout will be made within 30 days from the date of declaration through permissible electronic modes, after applicable tax deductions at source.
Key AGM Event Dates
The following table summarises the critical dates and details relating to the 35th AGM:
| Parameter: | Details |
|---|---|
| Event: | 35th Annual General Meeting |
| Date & Time: | August 14, 2026 at 12:15 hrs IST |
| Mode: | Video Conferencing / Other Audio-Visual Means |
| Dividend: | ₹5 per equity share (50% of face value) |
| Record Date: | July 31, 2026 |
| E-voting Cut-off Date: | August 7, 2026 |
| E-voting Period: | August 10, 2026 (09:00 hrs IST) to August 13, 2026 (17:00 hrs IST) |
| Results Publication Deadline: | On or before August 18, 2026 |
| Financial Year: | FY 2025-26 |
Ordinary and Special Business at the AGM
The AGM agenda covers both ordinary and special business. Under ordinary business, shareholders will consider adoption of audited financial statements for FY 2025-26, declaration of the final dividend, and the re-appointment of Mr. Arun Kumar (DIN: 00084845) — Founder, Non-Executive Director and Chairperson — who retires by rotation and offers himself for re-appointment. Under special business, shareholders will vote on the following key proposals:
| Agenda Item: | Details |
|---|---|
| Item 4: | Payment of commission to Non-Executive Directors (NEDs) in the event of inadequacy of profit — up to ₹50,00,000 per NED per financial year, valid for three years commencing FY 2026-27 |
| Item 5: | Appointment of Mr. Aditya Arun Kumar (DIN: 06999081) as Non-Executive Director with effect from June 1, 2026 |
| Item 6: | Appointment of Mr. Venkata Seetharama Raju Pakalapati ("Ram") (DIN: 07500141) as Executive Director for three years effective June 1, 2026, with a fixed pay of ₹3.60 crores per annum and variable pay of 40% of fixed pay |
Board Transition and Director Profiles
Aditya Arun Kumar, aged approximately 37 years, transitioned from his role as Executive Director – Business Development to a Non-Executive Director effective June 1, 2026, in line with the promoters' stated objective of professionalising management. He holds a bachelor's degree in biomedical sciences from Newcastle University and a Master of Research in Biophysics from King's College, London, and has over 13 years of experience in the pharmaceutical industry. As at the date of the AGM Notice, Aditya holds 58,422 equity shares (~0.06% of paid-up capital).
Ram, aged approximately 53 years, has been associated with the Strides Group since 2007 and was appointed Chief Operating Officer (COO) effective March 1, 2024. He holds a post-graduate degree in Pharmaceutical Chemistry from BITS Pilani and brings over 30 years of pharmaceutical industry experience. His proposed remuneration as Executive Director includes a fixed pay of ₹3.60 crores per annum and variable pay of ₹1.44 crores per annum, with long-term incentives linked to manufacturing, supply chain leadership, ESG integration, and digital transformation goals over his three-year tenure. As at the date of the AGM Notice, Ram holds 44,000 equity shares (~0.048% of paid-up capital) and 20,000 stock options exercisable during FY27 and FY28.
FY 2025-26 Financial Highlights
The company reported strong consolidated financial performance for FY 2025-26, as summarised below:
| Metric: | FY26 | FY25 | YoY Change |
|---|---|---|---|
| Consolidated Revenue (₹ Mn): | 48,587 | 45,653 | +6.40% |
| Gross Margin (₹ Mn): | 29,000 | 25,854 | +12.20% |
| Gross Margin (%): | 59.70% | 56.60% | +310 bps |
| EBITDA (₹ Mn): | 9,253 | 8,028 | +15.30% |
| EBITDA Margin (%): | 19.00% | 17.60% | +140 bps |
| Operational PAT (₹ Mn): | 5,181 | 3,447 | +50.30% |
| Operational EPS (₹): | 56.20 | 37.50 | +50% |
| Standalone Revenue (₹ Mn): | 21,801 | 21,394 | +2.00% |
| Standalone EBITDA (₹ Mn): | 2,850 | 2,624 | +9.00% |
| Standalone Operational PAT (₹ Mn): | 1,004 | 592 | +70% |
The total dividend payout, if approved, would amount to approximately ₹461 million, representing a payout ratio of 25% on a standalone basis and 8% on a consolidated basis. Net debt stood at ₹14,365 million as at March 31, 2026, with the net debt-to-equity ratio improving to 0.46x from 0.59x in FY25. Return on Capital Employed (ROCE) improved to 15.76% in FY26 from 14.86% in FY25.
E-voting and Participation
Shareholders whose names appear in the Register of Members as on the cut-off date of August 7, 2026 are entitled to vote on the resolutions. Remote e-voting is available via KFin Technologies Limited at https://evoting.kfintech.com/ . Shareholders may also attend the AGM through VC/OAVM using the same credentials. Speaker registration for the AGM is open from August 10, 2026 (09:00 hrs IST) to August 12, 2026 (17:00 hrs IST). The scrutinizer for the AGM is Mr. Gigi Joseph K J, Practicing Company Secretary (ICSI Membership No. F6483), and results will be declared on or before August 18, 2026. The AGM Notice and Annual Report for FY 2025-26 are available on the company's website at www.strides.com and on the websites of BSE Limited and National Stock Exchange of India Limited.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE939A01011/285e0924a57c4161.pdf
Historical Stock Returns for Strides Pharma Science
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.01% | -2.84% | -6.76% | +26.17% | +17.06% | +34.02% |
How will the appointment of the new Executive Director impact the company's ESG integration and digital transformation goals over the next three years?
Will the improved net debt-to-equity ratio enable Strides Pharma to pursue strategic acquisitions or increase R&D investments in the coming fiscal year?
What is the management's outlook on sustaining the 50% growth in Operational PAT given the current global regulatory environment for generics?


































